Option chain shows key data for Ionix Technology Inc's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Ionix Technology Inc.

Ionix Technology Inc (OTC:IINX) Stock, Option Chain

Ionix Technology Inc

Wells Fargo analyst Michael Brown maintains Franklin Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEN#NYSE">BEN</a>) with a Equal-Weight and lowers the price target from $22.5 to $20.5.

News

Price Target

Analyst Ratings

Wells Fargo Maintains Equal-Weight on Franklin Resources, Lowers Price Target to $20.5

Goldman Sachs analyst Susan Maklari maintains Meritage Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTH#NYSE">MTH</a>) with a Buy and lowers the price target from $117.5 to $100.

Goldman Sachs Maintains Buy on Meritage Homes, Lowers Price Target to $100

Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) ("Illumina" or the "company") today announced unaudited preliminary financial results for the fourth quarter and fiscal year 2024 and preliminary outlook for fiscal year 2025 ahead of its presentation at the 43rd Annual J.P. Morgan Healthcare Conference on January&nbsp;14, 2025 at 9:00 a.m. Pacific Time (12:00 p.m. Eastern Time). The webcast can be accessed through Illumina's website at investor.illumina.com.
Core Illumina
<ul>
<li>Revenue of approximately $1.10 billion for Q4 2024, up 1% from Q4 2023</li>
<li>Revenue of approximately $4.33 billion for 2024, down 2% from 2023 (and on a constant currency basis)</li>
<li>GAAP operating margin of approximately 16.7% for Q4 2024 and 34.2% for 2024</li>
<li>Non-GAAP operating margin of approximately 19.7% for Q4 2024 and 21.3% for 2024</li>
<li>GAAP diluted EPS of approximately $0.77 - $0.79 for Q4 2024 and $5.65 - $5.67 for 2024</li>
<li>Non-GAAP diluted EPS of approximately $0.91 - $0.93 for Q4 2024 and $4.12 - $4.14 for 2024</li>
<li>Cash flow provided by operations of approximately $1.21 billion and free cash flow (cash flow provided by operations less capital expenditures) of approximately $1.07 billion for 2024</li>
<li>For fiscal year 2025, expect constant currency revenue growth in the low single digits (reported revenue in the range of approximately $4.28 billion to $4.4 billion), non-GAAP operating margin of approximately 23%, and non-GAAP diluted EPS growth of approximately 10%</li>
</ul>
As previously announced, the company expects to report its full fourth quarter and fiscal year 2024&nbsp;results following the close of market on Thursday, February 6, 2025. The unaudited results in this press release are preliminary and subject to the completion of accounting and annual audit procedures and are therefore subject to adjustment.

Earnings

Guidance

ILMN

Illumina Announces Preliminary Financials For Q4 2024 With $1.10B Revenue, 2024 Revenue At $4.33B, GAAP EPS $5.65-$5.67; Non-GAAP EPS $4.12-$4.14; Sees 2025 Revenue Outlook Of $4.28B-$4.4B, Non-GAAP Margin 23%, EPS Growth 10%

Contracts

FRSX

Foresight Signs Agreement To Supply Autonomous Drone Technology To A Drone Manufacturer In India, With Commercial Potential Up To  $2.5M By 2026

Biotech

General

PACB

PacBio And Radboud UMC Published Study In American Journal Of Human Genetics

Wells Fargo analyst Michael Brown maintains Brookfield Asset Mgmt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAM#NYSE">BAM</a>) with a Underweight and lowers the price target from $56 to $55.

Wells Fargo Maintains Underweight on Brookfield Asset Mgmt, Lowers Price Target to $55

Goldman Sachs analyst Eric Sheridan maintains MediaAlpha (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAX#NYSE">MAX</a>) with a Buy and lowers the price target from $26 to $23.

Goldman Sachs Maintains Buy on MediaAlpha, Lowers Price Target to $23

Jacobs Solutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/J#NYSE">J</a>) shares are trading higher premarket on Tuesday after the company stated that it had been chosen by Ireland&#8217;s National Transport Authority (NTA) to deliver Client Partner services for the BusConnects Dublin Core Bus <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/n42967332/jacobs-to-manage-major-infrastructure-project-for-irelands-national-transport-authority" rel="noreferrer noopener">Corridors Infrastructure Works Program</a>.
This decade-long initiative is expected to enhance walking, cycling and bus infrastructure across 12 core corridors in Dublin and the Greater Dublin Area.
Jacobs&#8217; team will support the delivery of 230 kilometers (~142 miles) of bus priority corridors, 200 kilometers (~124 miles) of cycle paths and improved pedestrian facilities.
&#8220;BusConnects Dublin aims to transform public transport and promote active travel as the viable and attractive choice for commuters and visitors, enhancing connectivity and community life, and supporting the economy and environment,&#8221; said Jacobs executive vice president Kate Kenny.
NTA Head of BusConnects Dublin Infrastructure Aidan Gallagher said, &#8220;BusConnects will deliver a better-connected Dublin with improved public transport, cycling and pedestrian infrastructure along the 12 spines.&#8221;
Notably, Jacobs supports clients across Ireland in sectors like Advanced Manufacturing, Energy, Life Sciences and Transportation.
The company&#8217;s key projects comprises BusConnects Cork, Dunkettle Interchange Upgrade, M28 Motorway and East Coast Railway Infrastructure Protection.
Investors can gain exposure to the stock via&nbsp;Professionally Managed Portfolios Otter Creek Focus Strategy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OCFS#NYSE">OCFS</a>) and Valued Advisers Trust Kovitz Core Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQTY#NYSE">EQTY</a>).
Price Action: J shares are up 2.03% at $137.00&nbsp;premarket at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/content/42232564/2-essential-data-center-solutions-providers-riding-the-ai-boom" target="_blank" rel="noreferrer noopener">2 Essential Data Center Solutions Providers Riding the AI Boom</a></li>
</ul>
Company photo of Dublin office

Equities

Large Cap

Movers

EQTY

Professionally Managed Portfolios Otter Creek Focus Strategy ETF

OCFS

Jacobs Solutions' Stock Rises On Securing Key Role In Dublin's BusConnects

Planet to Launch Pelican-2 Satellite & 36 SuperDoves On Jan. 14; SpaceX's Launch Window Opens At 10:49 a.m. PT

JPMorgan Chase today announced new responsibilities for several senior executives as it continues to build on its leadership positions across global financial services.
Daniel Pinto, President and Chief Operating Officer, who has served the firm for more than 40 years, has informed Chairman and Chief Executive Officer Jamie Dimon of his decision to retire at the end of 2026. Pinto will relinquish his responsibilities as President and COO as of June 30, 2025. This will allow him to effectively transition those responsibilities in the coming months. He will continue to serve the company as Vice Chairman of JPMorgan Chase working closely with and advising the CEO and other senior executives on key projects, client relationships and complex issues facing the firm.
Jennifer Piepszak, Co-Chief Executive Officer of the Commercial &amp; Investment Bank (CIB), has been named Chief Operating Officer of the company, effective immediately, working closely with Pinto over the next few months. In this role, Piepszak will manage and coordinate all Technology, Operations, Chief Administrative Office, Data &amp; Analytics, Corporate Strategy and Diversity, Equity &amp; Inclusion across the company, as well as overseeing the firm's Global Corporate Centers in India and the Philippines, which employ more than 80,000 professionals.
Doug Petno, Co-head of Global Banking, will succeed Piepszak as Co-Chief Executive Officer of the CIB, partnering with current CIB Co-CEO, Troy Rohrbaugh, to manage the business. John Simmons, head of Commercial Banking, will succeed Petno and join Filippo Gori as the new Co-head of Global Banking, both reporting to Petno and Rohrbaugh.

Management

Daniel Pinto, President And COO Of JP Morgan Has Informed The Company Of His Decision To Retire At The End Of 2026; Pinto Will Relinquish His Responsibilities As President And COO As Of June 30, 2025; Jennifer Piepszak, Co-Chief Executive Officer Of The Commercial & Investment Bank, Has Been Named COO Of The Company, Effective Immediately

HTCO

Caravelle International Group Appoints Shixuan He As CEO

HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) has outperformed the market over the past 10 years by 5.19% on an annualized basis producing an average annual return of 16.34%. Currently, HCA Healthcare has a market capitalization of $79.88 billion. 
Buying $100 In HCA: If an investor had bought $100 of HCA stock 10 years ago, it would be worth $454.14 today based on a price of $309.51 for HCA at the time of writing.
<h3>HCA Healthcare's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736864109_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning HCA Healthcare Stock In The Last 10 Years

In the current market session, Amphenol Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APH#NYSE">APH</a>) share price is at $68.88, after a 0.79% increase. Moreover, over the past month, the stock decreased by 7.97%, but in the past year, went up by 43.38%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1736864106_0.png" alt="Past Year Chart" />

<h3>Amphenol P/E Compared to Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Amphenol has a lower P/E than the aggregate P/E of 51.44 of the Electronic Equipment, Instruments &amp; Components industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1736864106_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

Price Over Earnings Overview: Amphenol

Goldman Sachs analyst Susan Maklari maintains Leggett &amp; Platt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEG#NYSE">LEG</a>) with a Neutral and lowers the price target from $14 to $12.

Goldman Sachs Maintains Neutral on Leggett & Platt, Lowers Price Target to $12

Wells Fargo analyst Michael Brown maintains Bridge Investment Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRDG#NYSE">BRDG</a>) with a Overweight and lowers the price target from $12 to $10.

BRDG

Wells Fargo Maintains Overweight on Bridge Investment Group, Lowers Price Target to $10

JMP Securities analyst Reni Benjamin maintains Werewolf Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOWL#NASDAQ">HOWL</a>) with a Market Outperform and lowers the price target from $12 to $4.

HOWL

JMP Securities Maintains Market Outperform on Werewolf Therapeutics, Lowers Price Target to $4

Wells Fargo analyst Michael Brown maintains Blue Owl Cap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWL#NYSE">OWL</a>) with a Equal-Weight and lowers the price target from $25 to $24.

Wells Fargo Maintains Equal-Weight on Blue Owl Cap, Lowers Price Target to $24

LEXX

Lexaria's Announces Partial Findings showing Oral DehydraTECH-Tirzepatide Produced Reduced Adverse Events Of 47% Compared To Injected Zepbound

<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="586" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/13201135/Top-Image-1024x586.jpg" alt="" class="wp-image-4615" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/13201135/Top-Image-1024x586.jpg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/13201135/Top-Image-300x172.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/13201135/Top-Image-768x440.jpg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/13201135/Top-Image.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h2 class="wp-block-heading">MicroStrategy As A Levered Play On Bitcoin</h2>
In recent years, MicroStrategy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) has emerged as a essentially a levered play on Bitcoin. Over the last year, for example, MicroStrategy was up 468%, while Bitcoin was up 105%. 
<figure class="wp-block-image aligncenter size-full"><img loading="lazy" decoding="async" width="820" height="368" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/13201322/MSTR-BTC-Chart.jpg" alt="" class="wp-image-4616" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/13201322/MSTR-BTC-Chart.jpg 820w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/13201322/MSTR-BTC-Chart-300x135.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/13201322/MSTR-BTC-Chart-768x345.jpg 768w" sizes="(max-width: 820px) 100vw, 820px" /></figure>
<h2 class="wp-block-heading">MicroStrategy&#8217;s Bitcoin Balance Sheet Strategy.&nbsp;</h2>
What drove MicroStrategy&#8217;s outperformance is its Bitcoin Balance Sheet Strategy. MicroStrategy CEO Michael Saylor is arguably the world&#8217;s leading cheerleader for Bitcoin. After having turned his company into a machine for acquiring Bitcoin, he presented his strategy to Microsoft Corporation&#8217;s board recently. 
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-4-3 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Microsoft Bitcoin Strategy - A Presentation by Michael Saylor" width="500" height="375" src="https://www.youtube.com/embed/cH2t6VOdgkE?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
The general gist of MicroStrategy&#8217;s Bitcoin strategy is this:&nbsp;
<ul>
<li>Make Bitcoin the company&#8217;s primary treasury asset over cash.&nbsp;</li>
<li>Leverage secondary share offerings and debt offerings to buy more Bitcoin.&nbsp;</li>
<li>Use its underlying business to generate revenue to service the debt incurred to buy more Bitcoin.&nbsp;</li>
<li>Attract Bitcoin enthusiasts as shareholders which supports the share price and facilitates secondary offerings used to buy more Bitcoin.&nbsp;</li>
</ul>
<h2 class="wp-block-heading">Maybe Another Company Can Do This Better</h2>
Last year, another company decided to adopt MicroStrategy&#8217;s Bitcoin Balance Sheet Strategy:&nbsp;Semler Scientific, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>).
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Semler Scientific has acquired 237 BTC for ~$23.3 million at ~$98,267 per <a href="https://twitter.com/hashtag/bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#bitcoin</a> and has generated BTC Yield of 99.3% since adopting our BTC treasury strategy in May 2024. As of 1/10/2025, we held 2,321 <a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> acquired for ~$191.9 million at ~$82,687 per bitcoin. <a href="https://twitter.com/search?q=%24SMLR&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$SMLR</a>
&mdash; Eric Semler (@SemlerEric) <a href="https://twitter.com/SemlerEric/status/1878790528738701464?ref_src=twsrc%5Etfw">January 13, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Semler would seem to have a couple of major advantages over MicroStrategy, from an investor&#8217;s perspective. To start with, Semler&#8217;s core business is profitable, unlike MicroStrategy&#8217;s. You can see this in the comparisons below (the quantitative ratings are via&nbsp;<a href="https://www.chartmill.com/home?a=221937">Chartmill</a>).&nbsp;
MicroStrategy:&nbsp;
<ul>
<li>Bitcoin value as a percentage of market cap: 51.8%&nbsp;</li>
<li>Overall fundamental rating: 2</li>
<li>Profitability rating:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;3</li>
<li>Health rating:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 2</li>
<li>Valuation rating:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 2</li>
<li>Last quarter&#8217;s earnings: missed on top and bottom lines; lost money.</li>
</ul>
Semler Scientific:
<ul>
<li>Bitcoin value as a percentage of market cap: 47.3%.&nbsp;</li>
<li>Overall fundamental rating: 6</li>
<li>Profitability rating:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;9</li>
<li>Health rating:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 8</li>
<li>Valuation rating:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 5</li>
<li>Last quarter&#8217;s earnings: beat on top and bottom lines; made money.&nbsp;</li>
</ul>
Another advantage Semler has is its current obscurity. We had never heard of the company until it appeared in our system&#8217;s&nbsp;<a href="https://portfolioarmor.substack.com/p/top-names-182025">top ten names</a>&nbsp;last week.&nbsp;
<figure class="wp-block-image aligncenter size-full"><a href="https://portfolioarmor.substack.com/p/top-names-182025"><img loading="lazy" decoding="async" width="927" height="825" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/13201737/Top-Names-Post.jpg" alt="" class="wp-image-4618" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/13201737/Top-Names-Post.jpg 927w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/13201737/Top-Names-Post-300x267.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/13201737/Top-Names-Post-768x683.jpg 768w" sizes="(max-width: 927px) 100vw, 927px" /></a></figure>
<h2 class="wp-block-heading">Semler Scientific May Have More Upside From Here</h2>
We have positions in both MicroStrategy and Semler Scientific, but Semler may have more upside than MicroStrategy from here. Its stronger fundamentals and more recent adoption of the Bitcoin Balance Sheet Strategy may mean it has more dry powder to acquire Bitcoin relative to its market cap. It already has almost as much Bitcoin as a percentage of market cap than MicroStrategy does, despite having followed this strategy for less than a year. And if it becomes harder to raise money to buy Bitcoin, having a profitable underlying business means Semler Scientific will continue to be able to buy Bitcoin.&nbsp;
As more investors find out about Semler Scientific and compare it to MicroStrategy, it may become a higher-levered play on Bitcoin than MicroStrategy.&nbsp;
We shared our Semler Scientific trades with our subscribers last week. If you&#8217;d like a heads up when we place our next trade, you can subscribe to our trading Substack/occasional email list below.&nbsp;
And if you are concerned about market contagion, you can&nbsp;download our optimal hedging app by aiming your iPhone camera at the QR code below (or by&nbsp;<a href="https://apps.apple.com/us/app/portfolio-armor/id394951144">tapping here</a>, if you&#8217;re reading this on your phone).&nbsp;
<figure class="wp-block-image size-full"><a href="https://apps.apple.com/us/app/portfolio-armor/id394951144"><img loading="lazy" decoding="async" width="200" height="197" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/13201900/QR-Code-3.jpg" alt="" class="wp-image-4624" /></a></figure>
If you&#8217;d like to stay in touch
You can scan for optimal hedges for individual securities, find our current top ten names, and create hedged portfolios on <a href="https://portfolioarmor.com/" target="_blank" rel="noreferrer noopener nofollow">our website</a>. You can also follow Portfolio Armor on X <a href="https://twitter.com/portfolioarmor">here</a>, or become a free subscriber to our trading Substack using the link below (we&#8217;re using that for our occasional emails now).
<figure class="wp-block-image aligncenter size-full"><a href="https://portfolioarmor.substack.com/"><img loading="lazy" decoding="async" width="602" height="418" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/13202032/Widget-3.jpg" alt="" class="wp-image-4626" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/13202032/Widget-3.jpg 602w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/13202032/Widget-3-300x208.jpg 300w" sizes="(max-width: 602px) 100vw, 602px" /></a></figure>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

MSTR

SMLR

A Better Way To Play Bitcoin?

Goldman Sachs analyst Susan Maklari maintains JELD-WEN Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JELD#NYSE">JELD</a>) with a Neutral and lowers the price target from $10 to $9.

Comments

Ionix Technology Inc

Ionix Technology Inc (IINX) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga